Meg Krench

Korsana Biosciences is a private biopharmaceutical company advancing a pipeline of potential best-in-class therapies for neurodegenerative diseases. In partnership with Paragon Therapeutics, we have developed Therapeutic Targeting (THETA™), a novel blood-brain barrier-penetrant shuttle platform designed to enable dramatically higher drug concentration inside the brain and overcome the limitations of earlier shuttle technologies. Our lead program is KRSA-028, an investigational, shuttled antibody targeting amyloid beta designed to be a best-in-class treatment for Alzheimer’s disease. Our mission is to advance precision-engineered therapies, designed to address some of the biggest unmet needs in medicine. For more information, please visit www.korsana.com

Draig Therapeutics is a clinical-stage company with a mission to transform treatments in Neuropsychiatry. The company is leveraging its founders’ unique scientific expertise in modulating the core glutamate / GABA pathways that play a critical role in neuropsychiatric diseases to advance a pipeline of groundbreaking therapies designed to address large unmet patient needs, including in Major Depressive Disorder (MDD). Draig is the Welsh word for ‘dragon’ and it reflects the company’s origins in Wales. The name and logo were inspired by this heritage, reflecting its scientific roots stemming from Cardiff University.

Eligo Bioscience is a biotechology company that develops a new class of biotherapeutics for microbiome precision-editing.

At QurAlis, we are neuro pioneers on a quest to cure. We work with a relentless pursuit of knowledge, a precise attention to craft, and an optimistic mindset to discover and develop effective precision medicines that will forever alter the trajectory of amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and other neurodegenerative diseases. Founded by an internationally recognized team of neurodegenerative biologists from Harvard Medical School and Harvard University, QurAlis is advancing a pipeline with therapeutic candidates that target specific components of ALS and FTD pathology and defined patient populations based on both disease-causing genetic mutation(s) and clinical biomarkers.

Biologics are transforming the treatment of numerous diseases, but many CNS diseases remain largely out of reach due to the challenge of crossing the blood-brain barrier and navigating the brain’s unique immune environment. Aliada is redefining what is possible in CNS drug development by building on a highly versatile and differentiated platform, with demonstrated proof of concept in NHPs. We are expanding this platform across a wide range of modalities, including monoclonal antibodies, enzymes, oligonucleotides, peptides, and other proteins. The delivery technology is customizable to CNS tissue and target localization via novel approaches to binding two distinct transport targets on the blood-brain barrier. In addition to the platform, Aliada is applying its novel technology to specific CNS target antibody binders and progressing these programs through preclinical evaluation.

Normunity is a biotechnology company creating novel anti-cancer therapies that address untapped biology at the interface of the immune system and the tumor to target mechanisms that impact tumor growth and circumvent immune surveillance and tumor clearance. The company is using these novel targets to build a pipeline of anti-cancer medicines, including therapeutic antibodies, bispecific antibodies, and payload-carrying biologics. The company’s lead program, NRM‑823, is a T cell engager with tumor-specific targeting for multiple solid tumors and is expected to enter the clinic in 2025. Normunity is located in Boston, MA, and New Haven, CT.

We are an R&D driven, AI-powered biopharma company committed to improving people’s lives and delivering compelling growth. We apply our deep understanding of the immune system to invent medicines and vaccines that treat and protect millions of people around the world, with an innovative pipeline that could benefit millions more. Our team is guided by one purpose: we chase the miracles of science to improve people’s lives; this inspires us to drive progress and deliver positive impact for our people and the communities we serve, by addressing the most urgent healthcare, environmental, and societal challenges of our time. Interactions with this account must comply with the Terms: https://bit.ly/sanofi-terms

Accelerating development of first-in-class therapeutics for unmet medical needs

Korsana Biosciences is a private biopharmaceutical company advancing a pipeline of potential best-in-class therapies for neurodegenerative diseases. In partnership with Paragon Therapeutics, we have developed Therapeutic Targeting (THETA™), a novel blood-brain barrier-penetrant shuttle platform designed to enable dramatically higher drug concentration inside the brain and overcome the limitations of earlier shuttle technologies. Our lead program is KRSA-028, an investigational, shuttled antibody targeting amyloid beta designed to be a best-in-class treatment for Alzheimer’s disease. Our mission is to advance precision-engineered therapies, designed to address some of the biggest unmet needs in medicine. For more information, please visit www.korsana.com

Draig Therapeutics is a clinical-stage company with a mission to transform treatments in Neuropsychiatry. The company is leveraging its founders’ unique scientific expertise in modulating the core glutamate / GABA pathways that play a critical role in neuropsychiatric diseases to advance a pipeline of groundbreaking therapies designed to address large unmet patient needs, including in Major Depressive Disorder (MDD). Draig is the Welsh word for ‘dragon’ and it reflects the company’s origins in Wales. The name and logo were inspired by this heritage, reflecting its scientific roots stemming from Cardiff University.

Eligo Bioscience is a biotechology company that develops a new class of biotherapeutics for microbiome precision-editing.

At QurAlis, we are neuro pioneers on a quest to cure. We work with a relentless pursuit of knowledge, a precise attention to craft, and an optimistic mindset to discover and develop effective precision medicines that will forever alter the trajectory of amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD), and other neurodegenerative diseases. Founded by an internationally recognized team of neurodegenerative biologists from Harvard Medical School and Harvard University, QurAlis is advancing a pipeline with therapeutic candidates that target specific components of ALS and FTD pathology and defined patient populations based on both disease-causing genetic mutation(s) and clinical biomarkers.

Biologics are transforming the treatment of numerous diseases, but many CNS diseases remain largely out of reach due to the challenge of crossing the blood-brain barrier and navigating the brain’s unique immune environment. Aliada is redefining what is possible in CNS drug development by building on a highly versatile and differentiated platform, with demonstrated proof of concept in NHPs. We are expanding this platform across a wide range of modalities, including monoclonal antibodies, enzymes, oligonucleotides, peptides, and other proteins. The delivery technology is customizable to CNS tissue and target localization via novel approaches to binding two distinct transport targets on the blood-brain barrier. In addition to the platform, Aliada is applying its novel technology to specific CNS target antibody binders and progressing these programs through preclinical evaluation.